- Home
- Europe Car T Cell Therapy Treatment Market
Europe CAR-T Cell Therapy Treatment Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-287 | No of pages: 210 | Format:
Europe CAR-T cell therapy treatment market is projected to register a CAGR of 29.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Market Segmentation:
Europe CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends & Forecast to 2028
Some of the major factors contributing to the growth of global CAR-T cell therapy treatment market are:
Increase in usage of CAR-T cell therapy for the treatment of cancer and infectious diseases
Rise in awareness about immunotherapies
Market Players:
The key market players for Europe CAR-T cell therapy treatment market are listed below:
Autolus
Amgen Inc.
bluebird bio, inc.
Adaptimmune Therapeutics plc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc
AbbVie Inc.
Novartis AG
Kite Pharma (A Subsidiary of Gilead Sciences, Inc.)
Cellectis
TC BIOPHARM
Celyad Oncology
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF EUROPE CAR-T CELL THERAPY TREATMENT MARKET 1.4 LIMITATIONS 1.5 MARKETS COVERED 2 MARKET SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 MULTIVARIATE MODELLING 2.7 PRODUCT LIFELINE CURVE 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.9 DBMR MARKET POSITION GRID 2.10 VENDOR SHARE ANALYSIS 2.11 MARKET PRODUCT COVERAGE GRID 2.12 SECONDARY SOURCES 2.13 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHT 5 EPIDEMIOLOGY 6 PIPELINE ANALYSIS 7 MARKET OVERVIEW 7.1 DRIVERS 7.1.1 INCREASE IN USAGE OF CAR-T CELL THERAPY FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 7.1.2 INCREASING PREVALENCE OF CANCER 7.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 7.1.4 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT 7.1.5 ADOPTION OF CAR-T CELL THERAPY TREATMENT IN EMERGING MARKETS 7.2 RESTRAINTS 7.2.1 ADVERSE SIDE EFFECTS OF THERAPIES 7.2.2 HIGH COST ASSOCIATED WITH THERAPIES 7.2.3 LOGISTIC CHALLENGE ASSOCIATED WITH CAR-T THERAPIES 7.2.4 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 7.3 OPPORTUNITIES 7.3.1 PRESENCE OF PIPELINE PRODUCTS 7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 7.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 7.4 CHALLENGES 7.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 7.4.2 LACK OF SKILLED PROFESSIONALS 8 IMPACT OF COVID-19 ON EUROPE CAR-T CELL THERAPY TREATMENT MARKET 8.1 IMPACT ON PRICE 8.2 IMPACT ON DEMAND 8.3 IMPACT ON SUPPLY CHAIN 8.4 STRATEGIC DECISION FOR MANUFACTURERS 8.5 CONCLUSION 9 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT 9.1 OVERVIEW 9.2 AUTOLOGOUS CAR-T CELLS 9.3 ALLOGENEIC CAR-T CELLS 10 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 10.1 OVERVIEW 10.2 FIRST GENERATION CAR-T CELLS 10.3 SECOND GENERATION CAR-T CELLS 10.4 THIRD GENERATION CAR-T CELLS 10.5 FOURTH GENERATION CAR-T CELLS 11 EUROPE CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS 11.1 OVERVIEW 11.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES 11.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19) 11.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30) 11.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22) 11.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20) 11.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33) 11.3 ANTIGENS ON SOLID TUMORS 11.3.1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER-2) 11.3.2 EPIDERMAL GROWTH FACTOR RECEPTORS VARIANT III (EGFRV-III) 11.3.3 MESOTHELIN (MSLN) 11.3.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) 11.3.5 INTERLEUKIN-13RA2 (IL13RA2) 11.3.6 DISIALOGANGLIOSIDE 2 (GD2) 11.3.7 GLYPICAN-3 (GPC3) 11.3.8 OTHERS 11.4 OTHERS 12 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND 12.1 OVERVIEW 12.2 YESCARTA 12.3 KYMRIAH 12.4 TECARTUS 12.5 OTHERS 13 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION 13.1 OVERVIEW 13.2 FOLLICULAR LYMPHOMA 13.3 DIFFUSE LARGE B-CELL LYMPHOMA 13.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) 13.5 MANTLE CELL LYMPHOMA 13.6 MULTIPLE MYELOMA 13.7 HEMATOLOGIC MALIGNANCIES 13.7.1 LEUKEMIA 13.7.2 LYMPHOMA 13.7.3 MYELOMA 13.7.4 OTHERS 13.8 LUNG CANCER 13.9 CHRONIC LYMPHOCYTIC LEUKEMIA 13.10 GASTRIC CANCER 13.11 PANCREATIC CANCER 13.12 BREAST CANCER 13.13 OTHERS 14 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER 14.1 OVERVIEW 14.2 HOSPITALS 14.3 SPECIALTY CLINICS 14.4 OTHERS 15 EUROPE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 15.1 OVERVIEW 15.2 HOSPITAL PHARMACY 15.3 OTHERS 16 EUROPE CAR-T CELL THERAPY TREATMENT MARKET BY GEOGRAPHY 16.1 EUROPE 16.1.1 GERMANY 16.1.2 U.K 16.1.3 FRANCE 16.1.4 ITALY 16.1.5 SPAIN 16.1.6 NETHERLANDS 16.1.7 RUSSIA 16.1.8 SWITZERLAND 16.1.9 BELGIUM 16.1.10 TURKEY 16.1.11 AUSTRIA 16.1.12 NORWAY 16.1.13 HUNGARY 16.1.14 LITHUANIA 16.1.15 IRELAND 16.1.16 POLAND 16.1.17 REST OF EUROPE 17 EUROPE CAR-T CELL THERAPY TREATMENT MARKET: COMPANY LANDSCAPE 17.1 COMPANY SHARE ANALYSIS: EUROPE 18 SWOT ANALYSIS 19 COMPANY PROFILE 19.1 KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.) 19.1.1 COMPANY SNAPSHOT 19.1.2 REVENUE ANALYSIS 19.1.3 COMPANY SHARE ANALYSIS 19.1.4 PRODUCT PORTFOLIO 19.1.5 RECENT DEVELOPMENTS 19.2 NOVARTIS AG 19.2.1 COMPANY SNAPSHOT 19.2.2 REVENUE ANALYSIS 19.2.3 COMPANY SHARE ANALYSIS 19.2.4 PRODUCT PORTFOLIO 19.2.5 RECENT DEVELOPMENTS 19.3 ABBVIE INC. 19.3.1 COMPANY SNAPSHOT 19.3.2 REVENUE ANALYSIS 19.3.3 PRODUCT PORTFOLIO 19.3.4 RECENT DEVELOPMENTS 19.4 ADAPTIMMUNE THERAPEUTICS PLC 19.4.1 COMPANY SNAPSHOT 19.4.2 REVENUE ANALYSIS 19.4.3 PRODUCT PORTFOLIO 19.4.4 RECENT DEVELOPMENTS 19.5 AMGEN INC. 19.5.1 COMPANY SNAPSHOT 19.5.2 REVENUE ANALYSIS 19.5.3 PIPELINE PRODUCT PORTFOLIO 19.5.4 RECENT DEVELOPMENTS 19.6 ATARA BIOTHERAPEUTICS, INC. 19.6.1 COMPANY SNAPSHOT 19.6.2 PIPELINE PRODUCT PORTFOLIO 19.6.3 RECENT DEVELOPMENTS 19.7 AURORA BIOPHARMA 19.7.1 COMPANY SNAPSHOT 19.7.2 PIPELINE PRODUCT PORTFOLIO 19.7.3 RECENT DEVELOPMENTS 19.8 AUTOLUS 19.8.1 COMPANY SNAPSHOT 19.8.2 PRODUCT PORTFOLIO 19.8.3 RECENT DEVELOPMENTS 19.9 BELLICUM PHAMACEUTICALS, INC. 19.9.1 COMPANY SNAPSHOT 19.9.2 REVENUE ANALYSIS 19.9.3 PRODUCT PORTFOLIO 19.9.4 RECENT DEVELOPMENTS 19.10 BIOATLA INC. 19.10.1 COMPANY SNAPSHOT 19.10.2 PRODUCT PORTFOLIO 19.10.3 RECENT DEVELOPMENTS 19.11 BLUEBIRD BIO, INC. 19.11.1 COMPANY SNAPSHOT 19.11.2 REVENUE ANALYSIS 19.11.3 PRODUCT PORTFOLIO 19.11.4 RECENT DEVELOPMENTS 19.12 BRISTOL-MYERS SQUIBB COMPANY 19.12.1 COMPANY SNAPSHOT 19.12.2 REVENUE ANALYSIS 19.12.3 PRODUCT PORTFOLIO 19.12.4 RECENT DEVELOPMENTS 19.13 CARINA BIOTECH 19.13.1 COMPANY SNAPSHOT 19.13.2 PRODUCT PORTFOLIO 19.13.3 RECENT DEVELOPMENTS 19.14 CARTHERICS PTY LTD 19.14.1 COMPANY SNAPSHOT 19.14.2 PRODUCT PORTFOLIO 19.14.3 RECENT DEVELOPMENTS 19.15 CARTESIAN THERAPEUTICS, INC. 19.15.1 COMPANY SNAPSHOT 19.15.2 PIPELINE PRODUCT PORTFOLIO 19.15.3 RECENT DEVELOPMENTS 19.16 CELLECTIS SA 19.16.1 COMPANY SNAPSHOT 19.16.2 REVENUE ANALYSIS 19.16.3 PRODUCT PORTFOLIO 19.16.4 RECENT DEVELOPMENTS 19.17 CELYAD ONCOLOGY SA 19.17.1 COMPANY SNAPSHOT 19.17.2 PIPELINE PRODUCT PORTFOLIO 19.17.3 RECENT DEVELOPMENTS 19.18 JOHNSON & JOHNSON SERVICES, INC. 19.18.1 COMPANY SNAPSHOT 19.18.2 REVENUE ANALYSIS 19.18.3 PRODUCT PORTFOLIO 19.18.4 RECENT DEVELOPMENTS 19.19 SORRENTO THERAPEUTICS, INC. 19.19.1 COMPANY SNAPSHOT 19.19.2 PIPELINE PRODUCT PORTFOLIO 19.19.3 RECENT DEVELOPMENTS 19.20 TC BIOPHARM LIMITED 19.20.1 COMPANY SNAPSHOT 19.20.2 PIPELINE PRODUCT PORTFOLIO 19.20.3 RECENT DEVELOPMENTS 19.21 TESSA THERAPEUTICS LTD. 19.21.1 COMPANY SNAPSHOT 19.21.2 PIPELINE PRODUCT PORTFOLIO 19.21.3 RECENT DEVELOPMENTS 19.22 TMUNITY THERAPEUTICS 19.22.1 COMPANY SNAPSHOT 19.22.2 PIPELINE PRODUCT PORTFOLIO 19.22.3 RECENT DEVELOPMENTS 19.23 MUSTANG BIO 19.23.1 COMPANY SNAPSHOT 19.23.2 PIPELINE PRODUCT PORTFOLIO 19.23.3 RECENT DEVELOPMENTS 19.24 XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.) 19.24.1 COMPANY SNAPSHOT 19.24.2 REVENUE ANALYSIS 19.24.3 PIPELINE PRODUCT PORTFOLIO 19.24.4 RECENT DEVELOPMENTS 19.25 ZIOPHARM ONCOLOGY, INC. 19.25.1 COMPANY SNAPSHOT 19.25.2 PRODUCT PORTFOLIO 19.25.3 RECENT DEVELOPMENTS 20 QUESTIONNAIRE 21 RELATED REPORTSSegmentation
Short Description Europe CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells, Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, Fourth Generation CAR-T Cells), Targeted Antigens (Antigens on Solid Tumors, Antigens on Hematologic Malignancies, Others), Brand (Yescarta, Kymriah, Tecartus, Others), Therapeutic Application (Hematological Malignancies, Pancreatic Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Multiple Myeloma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, Others), End User (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospitals Pharmacy, Others), Country (Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe) Industry Trends & Forecast to 2028 Market Definition: CAR-T cell therapy or chimeric antigen receptor T cells are those T cells which are genetically engineered in order to produce an artificial T-cell receptor which can be used as an immunotherapy for the treatment of various cancers. Chimeric antigen receptors are those receptor proteins that have been engineered in the laboratories to provide the T-cells with the novel ability to target a specific protein. Market Segmentation: The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end user and distribution channel. On the basis of product, the CAR-T cell therapy treatment market is segmented into autologous CAR-T cells and allogeneic CAR-T cells On the basis of structure, the CAR-T cell therapy treatment market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells and fourth generation CAR-T cells On the basis of targeted antigens, the CAR-T cell therapy treatment market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others On the basis of brand, the CAR-T cell therapy treatment market is segmented into yescarta, kymriah, tecartus and others On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others Market Players: The key market players for Europe CAR-T cell therapy treatment market are listed below: Autolus Amgen Inc. bluebird bio, inc. Adaptimmune Therapeutics plc. Bristol-Myers Squibb Company Johnson & Johnson Services, Inc AbbVie Inc. Novartis AG Kite Pharma (A Subsidiary of Gilead Sciences, Inc.) Cellectis TC BIOPHARM Celyad OncologyMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.